ConCallIQ
Go Pro

Glenmark Pharmaceuticals FY25 Annual Earnings Summary

4 quarters covered · ₹13,322 Cr revenue · ₹1,046 Cr PAT · 8.9% average EBITDA margin.

Total annual revenue: ₹13,322 Cr
Annual PAT: ₹1,046 Cr
Average margin: 8.9%
Promise delivery: 0%

Quarter-by-quarter progression

QuarterRevenuePATMarginSentiment
Q1 FY25₹3,244 Cr₹340 Cr18.8%neutral
Q2 FY25₹3,434 Cr₹354 Crneutral
Q3 FY25₹3,388 Cr₹348 Crbullish
Q4 FY25₹3,256 Cr₹4 Cr17.0%neutral

Management promises made during the year

US recovery expected in H2 FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY25
missed
Monroe plant resumption by end of FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY25
missed
India business to achieve 9-10% growth for FY25

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q4 FY25
missed

Risks flagged during the year

Q1 FY25 · high

Monroe facility has an FDA meeting in September 2024, but no restart timeline; Goa remediation completed but inspection pending. Delays could impact US launches.

Q2 FY25 · high

Monroe plant has been non-operational; any further delay in FDA clearance could prolong the $25-26M annual cash burn.

Q3 FY25 · high

The Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products. Management has limited visibility on timing.

Q4 FY25 · high

Pithampur plant under FDA discussion; Monroe plant awaiting inspection. Delays could impact U.S. launch timelines.

Q4 FY25 · high

ISB 2001 licensing deal is critical to fund IGI's $70M annual burn; any delay could pressure margins.

Q1 FY25 · medium

Semaglutide patent expiry in 2026 may shift patients from liraglutide to newer GLP-1s, potentially limiting liraglutide's revenue potential.

Q1 FY25 · medium

CFO guided working capital days to increase to ~75 days from current 62 days, driven by business growth and receivables, which could pressure cash flows.

Q2 FY25 · medium

US generic market faces low single-digit price erosion; margins remain under pressure from competition.

Q2 FY25 · medium

Lirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.

Q3 FY25 · medium

Adverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.

Q3 FY25 · medium

Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.

Q3 FY25 · medium

The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.

What changed through the year

G

Q1 FY25 · Full-year EBITDA margin guidance of ~19%

Management guided to approximately 19% EBITDA margin for FY25, supported by India growth, RYALTRIS ramp-up, and lower R&D spend.

G

Q1 FY25 · RYALTRIS sales target of $80 million in FY25

Management reiterated the target of $80 million in RYALTRIS sales for the full year, with new market launches expected in FY26.

G

Q1 FY25 · US recovery expected in H2 FY25

Management expects US business to recover in the second half of FY25, driven by respiratory product approvals and Monroe facility restart.

G

Q1 FY25 · IGI partnership expected in FY26

Management plans to partner IGI's clinical asset 2001 in FY26 after presenting data at ASH in December 2024.

G

Q2 FY25 · Full-year EBITDA margin of ~19%

Management expects FY25 EBITDA margin to be close to 19%, with gradual improvement of 1-1.5% per year thereafter.

G

Q2 FY25 · Monroe plant resumption by end of FY25

Management expects to reinitiate commercial production at Monroe before end of FY25, following FDA meeting.

G

Q2 FY25 · First respiratory launch in 6-9 months

Glenmark expects to launch its first respiratory product in the US within 6-9 months, pending approval.

G

Q2 FY25 · IGI partnership for ISB 2001 by FY26

Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.

G

Q3 FY25 · India business to achieve 9-10% growth for FY25

Management reiterated guidance of INR 1,100 crore per quarter average, implying 9-10% YoY growth for the full year.

G

Q3 FY25 · EBITDA margin improvement of 1-1.5% YoY

Management expects year-on-year EBITDA margin improvement of 1-1.5% going forward, driven by critical launches.

G

Q3 FY25 · Fluticasone 44 MDI approval in H1 FY26

The company expects approval for Fluticasone 44 mcg MDI in the first half of FY26, with potential for earlier approval.

G

Q3 FY25 · IGI to be self-funded from FY27 onwards

Management expects FY26 to be the last year of Glenmark's capital investment in IGI, with a partnership expected to fund IGI going forward.

G

Q4 FY25 · Revenue growth 10%-12% in FY26

Consolidated revenue from operations expected to grow 10%-12% year-over-year in FY2026.

G

Q4 FY25 · EBITDA margin 19%-20% in FY26

EBITDA margin guided to 19%-20% for FY2026, driven by Ryaltris, U.S. launches, and R&D efficiencies.

G

Q4 FY25 · Cash generation INR 300-400 crore in FY26

Free cash flow (post-interest and dividends) expected to be INR 300-400 crore in FY2026.

G

Q4 FY25 · Generic Flovent 44 mcg approval by end of Q2 FY26

Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.